These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 24783987)

  • 21. [Positioning of lopinavir/ritonavir in antiretroviral treatment schemes].
    Camacho Á; Rivero A
    Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():31-4. PubMed ID: 25542874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alteration of complement protein levels after antiretroviral therapy in HIV-infected persons.
    Spear GT; Olinger G; Sullivan BL; Landay AL; Kessler H; Connick E; Kuritzkes D; St Clair M; Spritzler J; Wu H; Lederman MM
    AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1713-5. PubMed ID: 10606095
    [No Abstract]   [Full Text] [Related]  

  • 23. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.
    Perez-Molina JA; Rubio R; Rivero A; Pasquau J; Suárez-Lozano I; Riera M; Estébanez M; Santos J; Sanz-Moreno J; Troya J; Mariño A; Antela A; Navarro J; Esteban H; Moreno S;
    Lancet Infect Dis; 2015 Jul; 15(7):775-84. PubMed ID: 26062881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Lopinavir/ritonavir in patients with human immunodeficiency virus infection in special situations].
    Tasias M; Aldeguer JL
    Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():18-21. PubMed ID: 25542871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Challenges of lopinavir/ritonavir in the chronicity of human immunodeficiency virus infection].
    Aguirrebengoa K
    Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():26-30. PubMed ID: 25542873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Porphyria cutanea tarda in an HIV-1-infected patient after the initiation of tipranavir/ritonavir: case report.
    Celesia BM; Onorante A; Nunnari G; Mughini MT; Mavilla S; Massimino SD; Russo R
    AIDS; 2007 Jul; 21(11):1495-6. PubMed ID: 17589203
    [No Abstract]   [Full Text] [Related]  

  • 28. Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks.
    Murphy RL
    Antivir Ther; 1999; 4 Suppl 3():85-7. PubMed ID: 16021877
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Lopinavir/ritonavir in human immunodeficiency virus-infected women].
    Téllez MJ
    Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():22-5. PubMed ID: 25542872
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Lopinavir/ritonavir in new simplification strategies in antiretroviral therapy].
    Sebastián Mde L; Pardo OB; Ortega FP
    Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():12-7. PubMed ID: 25542870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial.
    Lombardi F; Belmonti S; Quiros-Roldan E; Latini A; Castagna A; D'Ettorre G; Gagliardini R; Fabbiani M; Cauda R; De Luca A; Di Giambenedetto S;
    J Antimicrob Chemother; 2017 Jul; 72(7):2055-2059. PubMed ID: 28333353
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Ritonavir-boosted lopinavir monotherapy due to intolerance to nucleoside reverse transcriptase inhibitors in an HIV-infected paediatric patient].
    Espiau M; Soler-Palacín P; Borrull A; Figueras C
    Enferm Infecc Microbiol Clin; 2011 Apr; 29(4):319. PubMed ID: 21334110
    [No Abstract]   [Full Text] [Related]  

  • 33. Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor.
    Solas C; Poizot-Martin I; Drogoul MP; Ravaux I; Dhiver C; Lafeuillade A; Allegre T; Mokhtari M; Moreau J; Lepeu G; Petit N; Durand A; Lacarelle B
    Br J Clin Pharmacol; 2004 Apr; 57(4):436-40. PubMed ID: 15025741
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Atazanavir-induced nephrolithiasis].
    Valencia ME; Moreno V
    Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):134-5. PubMed ID: 19246127
    [No Abstract]   [Full Text] [Related]  

  • 35. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.
    De Meyer S; Lathouwers E; Dierynck I; De Paepe E; Van Baelen B; Vangeneugden T; Spinosa-Guzman S; Lefebvre E; Picchio G; de Béthune MP
    AIDS; 2009 Sep; 23(14):1829-40. PubMed ID: 19474650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine.
    Diaz-Brito V; León A; Knobel H; Peraire J; Domingo P; Clotet B; Dalmau D; Cruceta A; Arnaiz JA; Gatell JM; García F;
    Antivir Ther; 2012; 17(2):337-46. PubMed ID: 22293542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Simplification to monotherapy with lopinavir/ritonavir in adolescents with vertically acquired HIV-1 infection.
    Schenone E; Di Biagio A; Parisini A; Bruzzone B; Sticchi L; Calzi A; Nicco E; Secondo G; Viscoli C
    J Chemother; 2012 Feb; 24(1):56-8. PubMed ID: 22546725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
    Mo H; King MS; King K; Molla A; Brun S; Kempf DJ
    J Virol; 2005 Mar; 79(6):3329-38. PubMed ID: 15731227
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quality of life in asymptomatic patients with early HIV infection initiating antiretroviral therapy. Swiss HIV Cohort Study.
    Zinkernagel C; Ledergerber B; Battegay M; Cone RW; Vernazza P; Hirschel B; Opravil M
    AIDS; 1999 Aug; 13(12):1587-9. PubMed ID: 10465088
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.